Quantcast
Last updated on April 20, 2014 at 13:20 EDT

Latest pharmacokinetics Stories

2014-04-18 23:08:24

OMICS Group announces the 5th World Congress on Bioavailabity and Bioequivalence: Pharmaceutical R&D Summit during Sep 29 - Oct 01, 2014 at Baltimore, USA with the theme “Innovative Approaches of BABE to Revolutionize the Next Generation Medicine” Los Angeles, CA (PRWEB) April 18, 2014 BABE-2014 is all set to explore the innovations, advancements in the field of pharmaceutical industry, which shows significant impact on the development of new and improved generic drugs. These...

2014-04-10 08:28:35

DUBLIN, April 10, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/h9n884/pharmacokinetics) has announced the addition of the "Pharmacokinetics - Workshop for Beginners (Course, London) - 28th & 29th April 2014" [http://www.researchandmarkets.com/research/h9n884/pharmacokinetics ] conference to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) The Pharmacokinetics - Workshop for Beginners...

2014-04-08 12:30:53

DUBLIN, April 8, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/6d9skh/drug_delivery_in) has announced the addition of a new report "Drug Delivery in Central Nervous System Diseases - Technologies, Markets and Companies" [http://www.researchandmarkets.com/research/6d9skh/drug_delivery_in ] to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) The delivery of drugs to central nervous system (CNS)...

2014-04-02 16:31:56

SAN DIEGO, April 2, 2014 /PRNewswire/ -- Polaris Group announced today that Shaw T. Chen, M.D., Ph.D. has joined Polaris Pharmaceuticals, Inc. (a subsidiary of Polaris Group) as Executive Vice-President of Regulatory Affairs. Dr. Chen had previously been with the United States (US) Food & Drug Administration (FDA) for over 26 years in new drug development as a primary/supervisory medical staff. His achievements at the FDA included management of new drug review divisions, drafting...

2014-02-27 12:27:32

DUBLIN, Feb. 27, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/jfrr3h/therapeutic_drug ) has announced the addition of a new report "Concise Analysis of the International Therapeutic Drug Monitoring Market" to their offering. (Logo:http://photos.prnewswire.com/prnh/20130307/600769) This report deals with therapeutic drug monitoring, a multi-disciplinary clinical specialty, aimed at improving patient care by monitoring drug levels in the blood to...

2014-02-05 12:28:03

Over 400 subjects participating in phase 3 studies PINE BROOK, N.J., Feb. 5, 2014 /PRNewswire/ -- Elusys Therapeutics, Inc. (Elusys), a biopharmaceutical company developing antibody therapies to treat infectious disease, today announced it has completed enrollment in three phase 3 safety studies of ETI-204, an anti-toxin in development for the treatment of inhalational anthrax. Elusys also announced it has completed enrollment in an additional study to evaluate the tolerability...

2014-01-29 08:29:25

- Data expand potential indications both within schizophrenia and to other neuropsychiatric disorders - SEATTLE, Jan. 29, 2014 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced positive results from a Phase 2a clinical trial of OMS824, the company's phosphodiesterase 10 (PDE10) inhibitor, in which the drug was well tolerated and demonstrated comparable systemic pharmacokinetics when administered alone and concomitantly with approved antipsychotic agents in patients...

2014-01-23 12:29:16

SAN DIEGO, Jan. 23, 2014 /PRNewswire/ -- Formex, LLC ("Formex"), a leader in pharmaceutical formulation and clinical trial manufacturing, announced today its sponsorship of the 3rd Drug Formulation & Bioavailability Conference to be held in Boston, MA from January 27-29, 2014. Formex CSO Blair West, Ph.D. will be joined by distinguished speakers from Merck & Co, F Hoffman-La Roche, Novartis and Boehringer-Ingelheim for a discussion entitled "Accelerating Time to Market...

2014-01-17 08:22:49

ST. LOUIS, Jan. 17, 2014 /PRNewswire/ -- Sigma-Aldrich Corporation (NASDAQ: SIAL) today announced that Sigma Life Science, its innovative biological products and services business, will be launching the genetically-modified HepaRG human liver cell line, licensed from Biopredic, for hepatotoxicity and drug metabolism assays. Currently undergoing beta-testing by multiple contract research and pharmaceutical organizations, the assays will be publicly available later in Q1 2014 in a...

2014-01-08 20:21:21

SAN FRANCISCO, Jan. 8, 2014 /PRNewswire/ -- Nektar Therapeutics' (Nasdaq: NKTR) President and Chief Executive Officer, Howard W. Robin, is scheduled to present at the upcoming 32(nd) Annual J.P. Morgan Healthcare Conference in San Francisco at the Westin St. Francis Hotel on Tuesday, January 14, 2014 at 10:00 a.m. Pacific time. The presentation will be accessible via a Webcast through a link posted on the Investor Relations, Events Calendar section of the Nektar website:...